RT Journal Article SR Electronic T1 Inflammatory leptomeningeal cytokines mediate delayed COVID-19 encephalopathy JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.09.15.20195511 DO 10.1101/2020.09.15.20195511 A1 Jan Remsik A1 Jessica A. Wilcox A1 N. Esther Babady A1 Tracy A. McMillen A1 Behroze A. Vachha A1 Neil A. Halpern A1 Vikram Dhawan A1 Marc Rosenblum A1 Christine A. Iacobuzio-Donahue A1 Edward K. Avila A1 Bianca Santomasso A1 Adrienne Boire YR 2020 UL http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195511.abstract AB SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction. Here we show that a particularly vulnerable population with neurologic manifestations of COVID-19 harbor an influx of inflammatory cytokines within the cerebrospinal fluid in the absence of viral neuro-invasion. The majority of these inflammatory mediators are driven by type 2 interferon and are known to induce neuronal injury in other disease models. Levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks following convalescence from the acute respiratory infection. These prolonged neurologic sequelae following a systemic cytokine release syndrome lead to long-term neurocognitive dysfunction with a wide range of phenotypes.Competing Interest StatementA.B. is an inventor on United States Provisional Patent Application No.: 62/258,044 Modulating Permeability of The Blood Cerebrospinal Fluid Barrier. A.B. is an unpaid member of the Scientific Advisory Board of EVREN Technologies. Other authors declare no competing interests.Funding StatementThis work was supported by NCI P30 CA008748 (Cancer Center Support Grant); and The Pew Charitable Trusts GC241069, The Damon Runyon Cancer Research Foundation GC240764, The Pershing Square Sohn Cancer Research Alliance GC239280, The Baker Family Foundation, and The W.M. Keck Foundation (all to A.B.). J.R. is supported by The American Brain Tumor Association Basic Research Fellowship, The Terri Brodeur Breast Cancer Foundation Fellowship, and The Druckenmiller Center for Lung Cancer Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical statement. This study was conducted according to the principles expressed in the Declaration of Helsinki. Ethical approval for COVID-19-relared research was obtained from MSKCC Institutional Review Board (IRB) under protocol #20-006. Collection and use of clinical samples were approved by MSKCC IRB #06-107, #12-245, #13-039, and #18-505. Only clinical samples collected in excess of those needed for diagnostic and therapeutic procedures were used for research. All participants provided written informed consent for sample and clinical data collection and subsequent analyses.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesACE2angiotensin-converting enzyme 2AIEautoimmune encephalitisCAR Tchimeric antigen receptor T cellCCLC-C motif chemokine ligandCRPC-reactive proteinCSFcerebrospinal fluidCXCLC-X-C motif chemokine ligandDRSdisability rating scaleEEGelectroencephalographyELISAenzyme-linked immunosorbent assayGRDAgeneralized rhythmic delta activityICANImmune Effector Cell-Associated Neurotoxicity SyndromeIFNinterferonILinterleukinKPSKarnofsky performance statusLPlumbar punctureMRImagnetic resonance imagingMMP-10matrix metallopeptidase- 10MCP2monocyte chemoattractant protein-2PCRpolymerase chain reactionPDRposterior dominant rhythm.